In summary, our results demonstrate a high frequency of NTRK fusions and RET fusions/mutations in patients with thyroid cancer with RAI-resistant distant metastases, ATA high, or ATA intermediate risk of recurrence, whose tumors are negative for other mutations/fusions. The gene discussed is RET; the disease is thyroid gland carcinoma.